GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXT) » Definitions » Degree of Operating Leverage

LIXT (Lixte Biotechnology Holdings) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2007. Start your Free Trial

What is Lixte Biotechnology Holdings Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Lixte Biotechnology Holdings does not have enough data to calculate Degree of Operating Leverage.


Lixte Biotechnology Holdings Degree of Operating Leverage Historical Data

The historical data trend for Lixte Biotechnology Holdings's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Degree of Operating Leverage Chart

Lixte Biotechnology Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lixte Biotechnology Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lixte Biotechnology Holdings's Degree of Operating Leverage

For the Biotechnology subindustry, Lixte Biotechnology Holdings's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lixte Biotechnology Holdings's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's Degree of Operating Leverage falls into.


;
;

Lixte Biotechnology Holdings Degree of Operating Leverage Calculation

Lixte Biotechnology Holdings's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -3.311 (Mar. 2025) / -4.67 (Mar. 2024) - 1 )/( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 )
=-0.291/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Lixte Biotechnology Holdings  (NAS:LIXT) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Lixte Biotechnology Holdings Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Lixte Biotechnology Holdings Business Description

Traded in Other Exchanges
N/A
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Executives
Rene Bernards director KONINGSVAREN 37, ABCOUDE P7 1391AD
Van Der Baan Bastiaan Jeroen director HOGEWEG 4-H, AMSTERDAM P7 1098CB
Eric Forman 10 percent owner 117 E. 29TH ST., APT. 5A, NEW YORK NY 10016
Regina Brown director 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Glenn Krinsky 10 percent owner C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067
Yun Yen director 1301 OAKLAWN ROAD, ARCADIA CA 91006
Robert Greenberg 10 percent owner SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266
Gil Schwartzberg 10 percent owner 269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212
Philip F Palmedo director 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
John S Kovach director, 10 percent owner, officer: Pres., CFO & Secty 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
Stephen J. Forman director 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Hung Tak Ho 10 percent owner MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000
Robert N Weingarten officer: Vice President and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
James Miser officer: Chief Medical Officer 680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101
Jane Merrill Riggs 10 percent owner 4852 SAINT ANDRES AVENUE, LA VERNE CA 91750

Lixte Biotechnology Holdings Headlines

From GuruFocus